AN2 Therapeutics, Inc. Increase (Decrease) in Accounts Payable
AN2 Therapeutics, Inc. (ANTX) reported Increase (Decrease) in Accounts Payable of -$1.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$998.00K.
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$405.00K.
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $795.00K, a 50.50% decline year-over-year.
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $113.00K.
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$296.00K, a 146.18% decline from fiscal 2024.
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $641.00K, a 15.91% increase from fiscal 2023.
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $553.00K, a 77.85% decline from fiscal 2022.
- AN2 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $2.50M, a 498.80% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$998.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.40M 10-Q · filed 2026-08-11 | -$608.00K derived: sum of 3 quarters · filed 2026-08-11 | -$495.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$405.00K 10-Q · filed 2026-05-11 | $390.00K derived: sum of 2 quarters · filed 2026-05-11 | $503.00K derived: sum of 3 quarters · filed 2026-05-11 | -$457.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $795.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $908.00K derived: sum of 2 quarters · filed 2026-03-17 | -$52.00K derived: sum of 3 quarters · filed 2026-08-11 | -$296.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$847.00K derived: sum of 2 quarters · filed 2026-08-11 | -$1.09M 10-Q · filed 2025-11-12 | $515.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$960.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.20M 10-Q · filed 2026-08-11 | $402.00K derived: sum of 3 quarters · filed 2026-08-11 | $228.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$244.00K 10-Q · filed 2026-05-11 | $1.36M derived: sum of 2 quarters · filed 2026-05-11 | $1.19M derived: sum of 3 quarters · filed 2026-05-11 | $640.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.43M derived: sum of 2 quarters · filed 2026-03-17 | $884.00K derived: sum of 3 quarters · filed 2026-03-17 | $641.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | -$174.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$722.00K derived: sum of 2 quarters · filed 2025-11-12 | -$965.00K 10-Q · filed 2025-11-12 | -$3.07M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$548.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$791.00K 10-Q · filed 2025-08-12 | -$2.90M derived: sum of 3 quarters · filed 2025-08-12 | -$1.25M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$243.00K 10-Q · filed 2025-05-13 | -$2.35M derived: sum of 2 quarters · filed 2025-05-13 | -$699.00K derived: sum of 3 quarters · filed 2025-05-13 | -$1.11M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$456.00K derived: sum of 2 quarters · filed 2025-03-25 | -$870.00K derived: sum of 3 quarters · filed 2025-03-25 | $553.00K 10-K · filed 2025-03-25 |
| 2023-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.24M derived: sum of 2 quarters · filed 2024-11-13 | $2.66M 10-Q · filed 2024-11-13 | $3.34M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$414.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.01M 10-Q · filed 2024-08-13 | $1.69M derived: sum of 3 quarters · filed 2024-08-13 | $1.52M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.42M 10-Q · filed 2024-05-14 | $2.10M derived: sum of 2 quarters · filed 2024-05-14 | $1.93M derived: sum of 3 quarters · filed 2024-05-14 | $2.37M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $510.00K derived: sum of 2 quarters · filed 2024-03-29 | $951.00K derived: sum of 3 quarters · filed 2024-03-29 | $2.50M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $270.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.82M 10-Q · filed 2023-11-09 | $870.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $441.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.99M 10-Q · filed 2023-08-10 | $1.04M derived: sum of 3 quarters · filed 2023-08-10 | $1.75M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.55M 10-Q · filed 2023-05-11 | $600.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.31M derived: sum of 3 quarters · filed 2023-05-11 | $1.58M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$235.00K derived: sum of 2 quarters · filed 2023-03-29 | $38.00K derived: sum of 3 quarters · filed 2023-03-29 | $417.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $711.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $984.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.36M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $652.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $379.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |